EASTMAN CHEMICAL CO — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Eastman Chemical reported Q2 2026 sales of $2,513M (up 10% YoY from $2,287M), with adjusted EBIT of $320M (+16% YoY) and adjusted diluted EPS of $1.97 (up 23% from $1.60). The company achieved a 350-basis-point sequential adjusted EBIT margin improvement driven by 8% higher sales volume/mix, disciplined pricing in specialties, and spread expansion in Chemical Intermediates (39% revenue growth from 24% volume and 14% pricing). Full-year 2026 guidance unchanged: $125–150M cost savings on track, capex ~$400M, operating cash flow now expected to approach $900M (down from prior guidance of approaching 2025 levels due to inflationary A/R pressure). Q3 2026 adjusted EPS projected to approach Q2's $1.97.
Why this rating
Strong Q2 beat on volume, price, and margin expansion relative to dynamic market. Guidance narrowed but guidance maintained. No major M&A, restructuring, or capital allocation shifts. Ordinary quarterly beat for $8.5B company.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.